Searched for
GILEAD CANCER RESEARCH
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipelineGilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...- Homegrown cell, gene therapy pioneer ImmunoACT turns profitable in first year of opsImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ...
- Forging a new path: ET Women Ahead shines spotlight on the most successful women in India IncThe final list of 29 – selected from an initial list of 115 female leaders from corporate India – are the names to keenly watch for in the ...
- Cognizant extends partnership with biopharma firm Gilead, estimated deal size at $800 millionGilead has partnered with Cognizant for more than three years now to adopt technologies designed to run business operations, new product la...
- How a drug major profited by slow-walking a promising HIV therapyToday, a generation of expensive Gilead drugs containing the new iteration of tenofovir account for half of the market for HIV treatment an...
- Metabolic changes in plasma, immune cells associated with COVID-19 severity: StudyThe researchers collected 374 blood samples -- two draws per patient during the first week after being diagnosed with SARS-CoV-2 infection ...
- Local firms got voluntary license for more drugs during pandemicA voluntary licence (VL) is an authorisation given by the patent holder to a generic company to produce a patented drug while a compulsory ...
- Oxford Covid-19 vaccine tech maker Vaccitech targets $613 mn valuation in US IPOThe company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raise...
- Pfizer is on track to be first to find out if its Covid vaccine worksA wide range of symptoms and severity makes the evaluation of Covid-19 vaccines tricky. The U.S. Food and Drug Administration has said that...
- Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivirDrug patents in India are an important issue as many countries depend on generic drugmakers to make and sell cheaper versions of critical d...
- Strike when it’s hot! 58% stocks from this sector defy crisis to double pricesThis outperformance came after an underperformance of four years.
- Novartis's $475,000 cancer breakthrough heralds new era of curesThe U.S. Food and Drug Administration on Wednesday approved a radical new one-time treatment from the Swiss drugmaker, weeks earlier than e...
- Biologics enter top selling drugs’ listBiologics, also called biopharmaceuticals, have revolutionised treatment in chronic and serious illnesse and nudged traditional drugs out o...
- Glenmark rises armed with research after five year hiatusIt may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.
- US pipeline, MS drug key to Natco's futureIn 2012, the company secured India's first compulsory licence to launch the generic version of Nexavar, Bayer's drug for treating liver and...
- Government may negotiate price of patented drugs before market entryThe government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them ...
- We will deliver biotech at a Dollar a day. Wait and see: Yusuf Khwaja Hamied, Chairman of CiplaEvery country’s patent laws are need-based to that country. That’s what I am trying to fight, and nobody is listening, Hamied said.
- National Pharmaceutical Pricing Authority cuts prices of diabetes & heart-disease drugsThe biggest debate on price cuts is happening in the US with patients, insurers and the government joining in.
- Drug price cut of vital medicines a global phenomenonDrug companies say that they are not objecting to the control of healthcare costs, but it is the high-handed approach that is harming the i...
- Novartis patent verdict not a problem, other issues pose risks to Indian pharma innovationThe recent Supreme Court judgement against Novartis has reopened old debates on drug patents, affordable healthcare and India as a destinat...
Load More
